{"public_id":"cl_fefb9e6f8735febbf90c4f3ea6e2cccd","status":"active","superseded_by_public_id":null,"corpus_id":221362281,"text":"Treatment with anti-IL-17A antibody significantly reduces HCC nodule number and tumor size in NASH-HCC models.","confidence":0.85,"paper":{"corpus_id":221362281,"title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","url":"https://sah.borca.ai/papers/221362281"},"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_507acf8fbdcd355dc0b761ca19d2f307","name":"NASH-HCC models","description":"Mouse models of nonalcoholic steatohepatitis that progress to hepatocellular carcinoma, used to evaluate the effects of FGF21 and anti-IL-17A antibody.","types":["animal model"],"url":"https://sah.borca.ai/concepts/co_507acf8fbdcd355dc0b761ca19d2f307"},{"public_id":"co_53460378092a39d8199f6cf36396e785","name":"tumor size","description":"The size of hepatocellular carcinoma tumors, reduced by anti-IL-17A antibody treatment.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_53460378092a39d8199f6cf36396e785"},{"public_id":"co_97bcb9bfb9df54038befa2dab67bad7f","name":"HCC nodule number","description":"The count of hepatocellular carcinoma nodules, reduced by anti-IL-17A antibody treatment.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_97bcb9bfb9df54038befa2dab67bad7f"},{"public_id":"co_ab5fff522da66c26473322fd1248e467","name":"anti-IL-17A antibody","description":"An antibody that neutralizes IL-17A, used here to treat NASH-HCC models and reduce HCC nodule number and tumor size.","types":["therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_ab5fff522da66c26473322fd1248e467"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_fefb9e6f8735febbf90c4f3ea6e2cccd"}